Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$3.42 USD
-0.08 (-2.29%)
Updated Jul 25, 2024 04:00 PM ET
Pre-Market: $4.00 +0.58 (16.96%) 9:24 AM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MBRX 3.42 -0.08(-2.29%)
Will MBRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBRX
Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
MBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for MBRX
Moleculin Biotech files to sell common stock, warrants, no amount given
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
Roth MKM Remains a Buy on Moleculin Biotech (MBRX)
Buy Rating for Moleculin Biotech Backed by Annamycin’s Promising Clinical Trial Outcomes and Market Potential
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial